Prana Biotechnology Limited (PRAN) Announces Successful Results from Phase IIa Clinical Trial
Prana announced successful results from the Phase IIa clinical trial of PBT2 in Early Alzheimer’s disease. Prana is a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders. Prana Biotechnology Limited is hosting a conference call, to be simultaneously webcast Tuesday, February 26th at 5:00 pm Eastern Standard Time and Wednesday, February 27th at 9:00 a.m. Melbourne Time. This will involve a question and answer (Q&A) session that will follow management’s presentation. Interested parties may partake in the conference call by dialing the following numbers five minutes before the call begins. (800) 713-4218 US or Canada…